RHYTHM PHARMACEUTICALS, INC. (RYTM) /
The cash flow of RHYTHM PHARMACEUTICALS, INC. over the past 10 years
Chart RHYTHM PHARMACEUTICALS, INC.: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, RHYTHM PHARMACEUTICALS, INC.'s operating cash flow was -$115.67M and its capital expenditures $953K, leaving free cash flow of -$116.63M. Free cash flow was below zero in all 10 years shown. It ranged from -$173.71M in fiscal 2022 to -$24.28M in fiscal 2016. Capital expenditures were highest in fiscal 2019, at $3.38M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$115.67M | $953K | -$116.63M |
| 2024ended Dec 31, 2024 | -$113.88M | $0 | -$113.88M |
| 2023ended Dec 31, 2023 | -$136.16M | $47K | -$136.2M |
| 2022ended Dec 31, 2022 | -$173.43M | $281K | -$173.71M |
| 2021ended Dec 31, 2021 | -$146M | $434K | -$146.44M |
| 2020ended Dec 31, 2020 | -$121.98M | $214K | -$122.19M |
| 2019ended Dec 31, 2019 | -$122.75M | $3.38M | -$126.14M |
| 2018ended Dec 31, 2018 | -$62.06M | $722K | -$62.78M |
| 2017ended Dec 31, 2017 | -$29.46M | $133K | -$29.59M |
| 2016ended Dec 31, 2016 | -$23.22M | $1.06M | -$24.28M |
Fiscal years as RHYTHM PHARMACEUTICALS, INC. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on RHYTHM PHARMACEUTICALS, INC.
- The revenue of RHYTHM PHARMACEUTICALS, INC.
- The profitability of RHYTHM PHARMACEUTICALS, INC.
- The debt of RHYTHM PHARMACEUTICALS, INC.
- All of RHYTHM PHARMACEUTICALS, INC.'s financials, charted
Companies of a similar size
- HRHealthcare Realty Trust Inc
- BLDRBUILDERS FIRSTSOURCE, INC.
- AVAVAEROVIRONMENT, INC.
- INGRINGREDION INCORPORATED
- PEGAPEGASYSTEMS INC.
Not investment advice. This page shows what RHYTHM PHARMACEUTICALS, INC. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.